Cell Therapeutics' Pixantrone Advisory Committee May Include Updated Results Of Pivotal Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA declined to give the NME for recurring, aggressive non-Hodgkin's lymphoma priority review, but the firm hopes that progression free survival data and safety argument will be compelling to ODAC.